Affimed N.V. announced that two abstracts with its innate cell engager (ICE(R)) AFM24 have been accepted for the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 2 - 6, 2023 in Chicago, IL. Leveraging innate immunity with AFM24, a novel CD16A and epidermal growth factor receptor (EGFR) bispecific innate cell engager: Interim results for the non-small cell lung cancer (NSCLC) cohort. Leveraging innate immunity withAFM24, a novel CD 16A and epidermal growth factors receptor (EGFR) bis pecific innate cell engager: interim results for the non- small cell lung cancer (NSCL CRC) cohort.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.72 USD | -3.54% |
|
-5.45% | -8.48% |
06-12 | Transcript : Affimed N.V., Q1 2024 Earnings Call, Jun 12, 2024 | |
06-12 | Affimed N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-8.48% | 87.1M | |
+16.45% | 122B | |
+21.96% | 116B | |
+25.50% | 27.03B | |
-20.05% | 20.36B | |
-16.28% | 15.91B | |
-16.06% | 16.43B | |
-44.35% | 15.6B | |
+63.91% | 14.94B | |
+2.52% | 13.59B |
- Stock Market
- Equities
- AFMD Stock
- News Affimed N.V.
- Affimed Announces AFM24 Clinical Abstracts Accepted for the Annual Meeting of the American Society of Clinical Oncology American Society of Clinical Oncology